PDCD1 and esophageal squamous cell carcinoma: Given these encouraging trends for neoadjuvant regimens including anti-PD-1 therapy, the present study aimed to explore the safety and efficacy of anti-PD-1 therapy combined with chemotherapy for resectable ESCC in neoadjuvant settings.